Alterity Therapeutics (ATHE) surges on pharmaceutical patent

Shares of Alterity Therapeutics (ATHE) is surging today because of a patent approved by the U.S. Patent and Trademark Office that covers 150 therapeutic compositions designed to redistribute the labile iron implicated in Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions.

Alterity said its strategy is predicated on the hypothesis that its therapeutics can disrupt the underlying pathology of neurodegenerative conditions, in which labile iron is implicated in disease pathology.

This conditions that could be treated include Parkinsonian disorders such as Parkinson’s disease and Multiple System Atrophy, as well as Alzheimer’s disease, the company said. 

The patent gives Alterity 20 years of exclusivity.

Alterity’s most advanced compound, ATH434, is in clinical development for Multiple System Atrophy.

“This broad patent establishes an excellent foundation for the company to pursue multiple therapeutics across a spectrum of neurodegenerative disease,” said CEO Geoffrey Kempler.

Where to put $1,000 right now

STOP BUYING STOCKS RIGHT NOW … And start taking a serious look at options, the investment vehicle that is driving stocks like Tesla and Apple to historically unprecented highs. 

Subscribe below to get insight into options trades!

Jay Lorrence
Jay Lorrence

Investor of 12 years and Managing Editor of Money Midnight, a news outlet focused on highly profitable investment ideas and bold underground research.

Articles: 233

Newsletter Updates

Enter your email address below to subscribe to our newsletter